AI Article Synopsis
- The study assessed the midterm results of using the Cardiatis Multilayer Flow Modulator to treat visceral artery aneurysms in five male patients with an average age of 73, over a two-year follow-up period.
- All patients achieved technical success, with two experiencing complete aneurysm exclusion and sac shrinking, while two stents occluded without symptoms, and one patient had incomplete exclusion leading to sac reperfusion.
- The researchers concluded that more extensive data is necessary to confirm the effectiveness of this endovascular treatment method.
Article Abstract
Purpose: The present study was performed to analyze the midterm results (five consecutive patients, 2-year follow-up) of the endovascular management of visceral artery aneurysms using the Cardiatis Multilayer Flow Modulator (CMFM) (Cardiatis, Isnes, Belgium), a self-expandable stent.
Materials And Methods: From August 2009 to January 2011, we implanted five CMFMs in five patients (all men; mean age 73 years) to treat two common hepatic artery aneurysms, one celiac trunk aneurysm, one splenic artery aneurysm, and one superior mesenteric artery aneurysm (diameter 25-81 mm). The primary end point was technical success. The secondary end point was stent patency, absence of aneurysm rupture or reperfusion, and shrinking of the sac at 6-, 12-, and 24-month follow-up using computed tomography angiography. Follow-up ranged from 24 to 48 months (mean 31.2).
Results: Technical success was achieved in all patients. Complete exclusion of the aneurysm with sac shrinking was achieved in two patients. Two stents became occluded at 6- and 24-month follow-up, respectively; both patients were asymptomatic and were not retreated. One patient developed sac reperfusion due to incomplete aneurysm exclusion.
Conclusion: Long-term results in a wider population are needed to validate the effectiveness of the CMFM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-013-0705-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraventricular baclofen for the treatment of pediatric spasticity in cerebral palsy: technique and outcomes.
J Neurosurg Pediatr
January 2025
Departments of1Neurosurgery and.
Objective: Intraventricular baclofen (IVB) administration is used for the treatment of secondary dystonia associated with cerebral palsy (CP), but it has not been reported as a first-line infusion technique for spasticity. In this study, the authors report outcomes of patients with mixed or isolated spasticity treated with IVB administration.
Methods: A retrospective analysis was performed of consecutive patients treated with IVB between 2019 and 2023.
Objective: The objective of this study was to assess the complicated relationship between frailty, perioperative complications, and patient-reported outcomes (PROs) in elderly patients (≥ 75 years old) undergoing lumbar spine fusion (LSF).
Methods: Consecutive patients who underwent LSF between March 2019 and December 2021 were recruited in this study. Frail patients (modified frailty index [mFI] score ≥ 2) were propensity score matched to nonfrail patients (mFI score 0-1) on the basis of age, sex, and the number of fused levels.
Technical Pearls for Breast Reconstruction in Low BMI Asian Women With the Profunda Artery Perforator Flap.
Microsurgery
January 2025
Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
Background: The deep inferior epigastric perforator (DIEP) flap is currently the gold standard for autologous breast reconstruction. In cases where the DIEP is contraindicated, the profunda artery perforator (PAP) flap is now the preferred second-line option in our institution. The PAP flap poses unique challenges to the reconstructive surgeon, especially in Asian women with low body mass index (BMI).
View Article and Find Full Text PDFCirculating PD-1hi CXCR5- and CXCR5+ CD4 T cells are elevated in patients with newly diagnosed Giant Cell Arteritis and predict relapse.
Rheumatology (Oxford)
January 2025
Department of Rheumatology, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.
Objectives: Giant cell arteritis (GCA) is a large/medium-vessel granulomatous vasculitis, and the PD-1/PD-L1 coinhibitory pathway seems to be implicated in its pathogenesis. CD4 T cells expressing high PD-1 levels, CD4+CXCR5-PD-1hi peripheral helper (Tph) and CD4+CXCR5+PD-1hi follicular helper T cells (Tfh), are key mediators of autoimmunity. Their frequencies are elevated in the peripheral blood of subjects with several autoimmune conditions but have not been investigated in GCA.
View Article and Find Full Text PDFClinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Objectives: This study aimed to evaluate the incidence and clinical significance of coexistence of anti-aminoacyl-tRNA synthetase (anti-ARS) antibody in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM).
Methods: We assessed a cohort of 246 consecutive patients with anti-MDA5 + DM. Clinical characteristics and survival rates were compared between patients with and without anti-ARS antibodies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!